Most Read Articles
Fiel Soliven, 2 years ago
The correlation of co-morbidities with viral hepatitis type based on liver fibrosis stage assessed on shearwave elastography was determined in this study.
one year ago
Sofosbuvir-velpatasvir combination is safe and highly effective in patients with genotype 1 or 3 hepatitis C virus (HCV) infection, according to a randomized, phase 2 open-label study.
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Sofosbuvir may be safely combined with many common antiretrovirals in a study among noncirrhotic patients with chronic hepatitis C and stable HIV infection.

Treatment of alcoholic hepatitis – Role of S-adenosyl-L-methionine (SAMe)

8 months ago
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 2 years ago
The correlation of co-morbidities with viral hepatitis type based on liver fibrosis stage assessed on shearwave elastography was determined in this study.
one year ago
Sofosbuvir-velpatasvir combination is safe and highly effective in patients with genotype 1 or 3 hepatitis C virus (HCV) infection, according to a randomized, phase 2 open-label study.
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Sofosbuvir may be safely combined with many common antiretrovirals in a study among noncirrhotic patients with chronic hepatitis C and stable HIV infection.